Pfizer (PFE) Accumulated Depreciation & Amortization (2009 - 2026)

Pfizer (PFE) has 18 years of Accumulated Depreciation & Amortization data on file, last reported at $1.6 billion in Q1 2026.

• Quarterly Accumulated Depreciation & Amortization changed 0.31% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (changed 0.31% YoY) and the FY2025 annual result came in at $6.6 billion, down 6.0% from the prior year.
• Accumulated Depreciation & Amortization slipped to $1.6 billion in Q1 2026 per PFE's latest filing, from $6.6 billion in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $7.0 billion in Q4 2024 and bottomed at $1.5 billion in Q2 2023.
• The 5-year median for Accumulated Depreciation & Amortization is $3.4 billion (2022), against an average of $3.8 billion.
• The widest annual swing landed in 2024, when Accumulated Depreciation & Amortization sank 43.46%; it then jumped 87.46% in 2025.
• Tracing PFE's Accumulated Depreciation & Amortization over 5 years: stood at $5.1 billion in 2022, then rose by 24.21% to $6.3 billion in 2023, then grew by 11.49% to $7.0 billion in 2024, then slipped by 6.0% to $6.6 billion in 2025, then tumbled by 75.53% to $1.6 billion in 2026.
• Per Business Quant, the three latest PFE Accumulated Depreciation & Amortization figures stand at $1.6 billion (Q1 2026), $6.6 billion (Q4 2025), and $4.9 billion (Q3 2025).

Peer Comparison